Phlebitis

EQS-News: TVM CAPITAL LIFE SCIENCE TO PARTICIPATE IN LSI USA ’24 EMERGING MEDTECH SUMMIT 2024

Retrieved on: 
Wednesday, April 10, 2024
Radiation, Thrombosis, Partner (business rank), Infection, Intelligence, TVM, Risk, General partnership, Patient, Eye injury, Standard of care, AI, Workflow, Investment, LSI, Phlebitis, Eli Lilly and Company, Vector, Therapy, FDA, Physician, Health, PFC, Medical imaging

Munich, Germany and Montreal, Quebec, Canada (March 13, 2024) – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that the Company will participate in the sixth annual LSI USA ’24 Emerging Medtech Summit 2024, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies.

Key Points: 
  • Munich, Germany and Montreal, Quebec, Canada (March 13, 2024) – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that the Company will participate in the sixth annual LSI USA ’24 Emerging Medtech Summit 2024, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies.
  • The conference will take place March 18-22, 2024, in Dana Point, California, USA.
  • "Medtech innovation continues to be at the forefront of healthcare advancement, driving transformative changes in patient care, operational efficiency and cost reduction.
  • As part of our commercial-stage medical technologies investment strategy, TVM seeks breakthrough solutions that align with emerging trends and could redefine the standard of care.

TVM Capital Life Science to Participate in LSI USA ’24 Emerging Medtech Summit 2024

Retrieved on: 
Wednesday, March 13, 2024
Radiation, Thrombosis, Partner (business rank), Infection, Intelligence, TVM, Risk, General partnership, Patient, Eye injury, Standard of care, AI, Workflow, Investment, Medtech, LSI, Phlebitis, Eli Lilly and Company, Vector, Therapy, FDA, Physician, Health, PFC, Medical imaging

MUNICH, Germany and MONTREAL, March 13, 2024 (GLOBE NEWSWIRE) -- TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that the Company will participate in the sixth annual LSI USA ’24 Emerging Medtech Summit 2024, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies.

Key Points: 
  • MUNICH, Germany and MONTREAL, March 13, 2024 (GLOBE NEWSWIRE) -- TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that the Company will participate in the sixth annual LSI USA ’24 Emerging Medtech Summit 2024, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies.
  • The conference will take place March 18-22, 2024, in Dana Point, California, USA.
  • “Medtech innovation continues to be at the forefront of healthcare advancement, driving transformative changes in patient care, operational efficiency and cost reduction.
  • As part of our commercial-stage medical technologies investment strategy, TVM seeks breakthrough solutions that align with emerging trends and could redefine the standard of care.

FDA Approves New Antibiotic for Three Different Uses

Retrieved on: 
Wednesday, April 3, 2024
Daptomycin, Research, Hypersensitivity, Hypokalemia, Fungal infection, Aztreonam, Dizziness, Pneumonia, Survival, Dysgeusia, Potassium, Seizure, Abdominal pain, Dietary supplement, CABP, Headache, Patient, Public, Insomnia, Bacterial pneumonia, Food and Drug Administration, Animal, Bilirubin, Diarrhea, History, Mortality, Vancomycin, Leukopenia, Clostridioides, Human services, Injection site reaction, Nausea, Rash, Priority review, Bronchopneumonia, Skin, Fever, Heated tobacco product, Ceftriaxone, Safety, SAB, Anemia, Division, Phlebitis, Cosmetics, Vaccine, Infection, Food, Vomiting, Blood, Multimedia, FDA, Periodic breathing, ABSSSI, Pharmaceutical industry

"The FDA will continue our important work in this area as part of our efforts to protect the public health."

Key Points: 
  • "The FDA will continue our important work in this area as part of our efforts to protect the public health."
  • Zevtera's efficacy in treating SAB was evaluated in a randomized, controlled, double-blind, multinational, multicenter trial .
  • In the trial, researchers randomly assigned 390 subjects to receive Zevtera (192 subjects) or daptomycin plus optional aztreonam [the comparator] (198 subjects).
  • A total of 69.8% of subjects who received Zevtera achieved overall success compared to 68.7% of subjects who received the comparator.

Access Vascular Supports Updated Standards of Care Emphasizing New Materials to Reduce Catheter Complications

Retrieved on: 
Wednesday, February 28, 2024
Nursing, Medical Supplies, Health, Medical Devices, Hospitals, Other Health, Managed Care, Bloodstream infections, Thrombosis, Occlusion, INS, PICC, Phlebitis, Catheter, AVI, Patient, HBM, Risk

Access Vascular, Inc. (AVI), a company addressing the most common and costly vascular access complications with its novel hydrophilic biomaterial platform, today announced that the Infusion Nurses Society (INS) has updated its standard of care to include innovative catheter materials, to reduce the risk of vascular access complications.

Key Points: 
  • Access Vascular, Inc. (AVI), a company addressing the most common and costly vascular access complications with its novel hydrophilic biomaterial platform, today announced that the Infusion Nurses Society (INS) has updated its standard of care to include innovative catheter materials, to reduce the risk of vascular access complications.
  • The new INS guidelines cite improvements in catheter materials as having the potential to reduce complications such as phlebitis, occlusion, and thrombosis.1 The guidelines also advise healthcare providers to consider using devices made of novel materials in populations with high rates of occlusion or thrombosis.
  • Studies have shown that peripherally inserted central catheters (PICC) and midline catheters made using AVI’s MIMIX™ hydrophilic biomaterial (HBM) offer lower rates of failure,2 occlusion,3 bacterial adhesion and thrombus accumulation,4 compared with catheters made from conventional polyurethane materials.
  • “Rates of bloodstream infections have soared, at great cost to the U.S. healthcare system and, most importantly, leading to a myriad of patient complications,” said James Biggins, Founder and CEO of Access Vascular.

Human medicines European public assessment report (EPAR): Mycamine, micafungin, Date of authorisation: 25/04/2008, Revision: 18, Status: Authorised

Retrieved on: 
Tuesday, January 9, 2024
Fungal infection, Liver, Marketing, Chills, INN, Risk, Leukopenia, Hypotension, Fungus, Hypertension, Nausea, DNA, Inflammation, Liver disease, Anatomy, IIA, CHMP, Diarrhea, Fever, Infection, ATC, Hepatomegaly, European, Neutrophil, Neoplasm, HIV, Tachycardia, Anemia, Hypocalcemia, Hypokalemia, Patient, Medical Subject Headings, Caspofungin, European Commission, Echinocandin, Kidney failure, International, Bilirubin, Neutropenia, Blood, Language, Thrombocytopenia, Magnesium, Select, Medicine, Vomiting, Phlebitis, Amphotericin B, Allergy, Fluconazole, Headache, Rat, Haematopoiesis, Committee, Checklist, Alkaline phosphatase, Rash, Medical device

Human medicines European public assessment report (EPAR): Mycamine, micafungin, Date of authorisation: 25/04/2008, Revision: 18, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Mycamine, micafungin, Date of authorisation: 25/04/2008, Revision: 18, Status: Authorised

Access Vascular Inc. Announces Publication of Study Showing Significantly Reduced Failure Rates with its HydroPICC® Catheter

Retrieved on: 
Tuesday, July 25, 2023
Biotechnology, Health, Clinical Trials, Medical Devices, Journal of Materials Science: Materials in Medicine, Infection, AVI, PICC, Thrombosis, Phlebitis, Patient, Standard of care, Risk, Access, RN, Materials science, Medical device, Medical imaging, Medicine

The retrospective study demonstrated that HydroPICC significantly reduced clot formation and failures, compared with conventional polyurethane PICCs.

Key Points: 
  • The retrospective study demonstrated that HydroPICC significantly reduced clot formation and failures, compared with conventional polyurethane PICCs.
  • This retrospective study investigated whether the HydroPICC, constructed of a novel hydrophilic biomaterial with MIMIX™ technology, reduced thrombotic catheter occlusions, compared to polyurethane devices, in 121 patients who received a PICC as part of their medical care.
  • The study results demonstrated no occlusions or replacements in the 60 HydroPICC insertions, while 13 catheter occlusions were reported in the 61 polyurethane insertions catheter group and eight outright PICC replacements (13%).
  • Recently published clinical data for the HydroMID midline catheter showed six-fold failure reduction compared with a standard polyurethane device.

Global IV Tubing Sets and Accessories Market Report 2023: Increasing Number of Surgical Procedures Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 1, 2023
Medical Devices, Health, Infection, Infiltration, Conditional sentence, Injury, Growth, Cancer, IV, Prevalence, Diabetes, Patient, Phlebitis, Medical device

The global market for IV tubing sets and accessories has been witnessing a steady growth, propelled by several factors including the rising prevalence of chronic diseases, the increasing number of surgical procedures, and the advancements in technology

Key Points: 
  • The global market for IV tubing sets and accessories has been witnessing a steady growth, propelled by several factors including the rising prevalence of chronic diseases, the increasing number of surgical procedures, and the advancements in technology
    Chronic conditions like cancer, diabetes, and heart disease often require regular administration of medications and fluids, driving the demand for IV tubing sets and accessories.
  • Additionally, surgical procedures often involve the use of IV sets for anaesthesia administration, fluid replacement, and post-operative medication delivery, further contributing to the market's expansion
    The market is also being shaped by technological innovations.
  • For instance, the development of safety IV sets, which are designed to minimize needlestick injuries and infection risks, has led to increased adoption of these products.
  • Furthermore, the need for skilled healthcare professionals to manage IV therapy can limit the growth of the market in regions with a shortage of trained staff

EQS-News: TVM Capital Life Science to participate in LSI USA ’23 Emerging Medtech Summit 2023

Retrieved on: 
Friday, March 17, 2023
Magnet, Infection, CE, TVM, Radiation, PFC, Therapy, Partnership, Workflow, Pathology, CAD, General partnership, Sleep apnea, Partner (business rank), Science, Creativity, II, Knee pain, Thrombosis, Motion, Phlebitis, Investment, Risk, Patient, LSI, Growth, Eli Lilly and Company, Eye injury, AI, FDA, Health Canada, Summit, Knee, Pharmaceutical industry, Renewable energy, Medical imaging, Medical device, EU

Montreal, Canada / Munich, Germany – 17 March 2023 – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that Dr. Luc Marengère, Managing Partner, and Dr. Sascha Berger, General Partner of TVM, will participate in the upcoming LSI USA ’23 Emerging Medtech Summit 2023, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies.

Key Points: 
  • Montreal, Canada / Munich, Germany – 17 March 2023 – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that Dr. Luc Marengère, Managing Partner, and Dr. Sascha Berger, General Partner of TVM, will participate in the upcoming LSI USA ’23 Emerging Medtech Summit 2023, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies.
  • The conference will take place March 20-23, 2023, in Dana Point, California, USA.
  • “Medtech innovation plays a pivotal role in the healthcare ecosystem and has the potential to revolutionize the industry by improving patient outcomes, increasing efficiency, and reducing costs.
  • One key component of our strategy is to invest in disruptive, breakthrough, commercial-stage technologies that map essential future trends and significantly transform current standard-of-care.

TVM Capital Life Science to participate in LSI USA ’23 Emerging Medtech Summit 2023

Retrieved on: 
Friday, March 17, 2023
Magnet, Infection, CE, TVM, Radiation, PFC, Therapy, Partnership, Workflow, Pathology, CAD, General partnership, Sleep apnea, Partner (business rank), Science, Creativity, II, Knee pain, Thrombosis, Motion, Phlebitis, Investment, Risk, Patient, LSI, Growth, Eli Lilly and Company, Eye injury, AI, FDA, Health Canada, Summit, Knee, Pharmaceutical industry, Renewable energy, Medical imaging, Medical device, EU

MONTREAL and MUNICH, Germany, March 17, 2023 (GLOBE NEWSWIRE) -- TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that Dr. Luc Marengère, Managing Partner, and Dr. Sascha Berger, General Partner of TVM, will participate in the upcoming LSI USA ’23 Emerging Medtech Summit 2023, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies.

Key Points: 
  • MONTREAL and MUNICH, Germany, March 17, 2023 (GLOBE NEWSWIRE) -- TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that Dr. Luc Marengère, Managing Partner, and Dr. Sascha Berger, General Partner of TVM, will participate in the upcoming LSI USA ’23 Emerging Medtech Summit 2023, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies.
  • The conference will take place March 20-23, 2023, in Dana Point, California, USA.
  • “Medtech innovation plays a pivotal role in the healthcare ecosystem and has the potential to revolutionize the industry by improving patient outcomes, increasing efficiency, and reducing costs.
  • One key component of our strategy is to invest in disruptive, breakthrough, commercial-stage technologies that map essential future trends and significantly transform current standard-of-care.

Riverside Medical Center Performs First In-Patient Use of Biomaterial-Based HydroPICC® Dual Lumen Catheter

Retrieved on: 
Monday, December 12, 2022
Thrombosis, AVI, Phlebitis, Family, Water, FDA, Hospital, Elective surgery, Death, Neurosurgery, Deep vein thrombosis, Infection, Trauma, Riverside Medical Center, PICC, Patient, Truven Health Analytics, Medical imaging

(AVI) today announced that Riverside Medical Center, located just outside the Chicago area, was the first in the nation to use its HydroPICC® Dual-Lumen catheter in a patient.

Key Points: 
  • (AVI) today announced that Riverside Medical Center, located just outside the Chicago area, was the first in the nation to use its HydroPICC® Dual-Lumen catheter in a patient.
  • Riverside Medical Center is a 300-bed Level II Trauma hospital that provides a full scope of inpatient and outpatient care.
  • Riverside is the area's only Magnet® Recognized hospital and ranks among the top 5 percent of hospitals nationwide for clinical performance.
  • Riverside Medical Group includes more than 140 primary and specialty care providers that deliver care at sites throughout the region.